A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi

Long title

A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination with ALVAC-HIV (vCP-1452) and Remune or placebo while maintaining optimal therapeutic viral suppression

Date receipt dossier

13 October 2000

Company / Sponsor

Glaxo Wellcome

Phase

III

Treated organism

Humans

Indication category

Infectious disease

Disease

AIDS

Therapeutic approach

Immunotherapy

Genetic modification

vCP-1452

Method of transfer of nucleic acid of interest

Attenuated Canarypox Virus (ALVAC)

Administered biological material

Recombinant Canarypox Virus

Route of administration

Intramuscular

Locations in Belgium

Centre Hospitalier Universitaire St Pierre, Brussels

Type of procedure

Contained use only

Notes

Sponsor of the study: Glaxo Wellcome; Manufacturer of the GMO: Aventis-Pasteur S.A.

Pharmaceutical study code

PROB3005